Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

September 28, 2022

Study Completion Date

June 6, 2023

Conditions
Sjögren Syndrome
Interventions
DRUG

CFZ533

Biological

OTHER

Placebo

liquid placebo for injections

Trial Locations (71)

1023

Novartis Investigative Site, Budapest

1090

Novartis Investigative Site, Vienna

1426

Novartis Investigative Site, CABA

6009

Novartis Investigative Site, Nedlands

6720

Novartis Investigative Site, Szeged

6740

Novartis Investigative Site, Concepción

8000

Novartis Investigative Site, Székesfehérvár

8036

Novartis Investigative Site, Graz

11501

Novartis Investigative Site, Mineola

19104

Novartis Investigative Site, Philadelphia

20132

Novartis Investigative Site, Milan

21224

Novartis Investigative Site, Baltimore

29200

Novartis Investigative Site, Brest

30096

Novartis Investigative Site, Duluth

33100

Novartis Investigative Site, Udine

44281

Novartis Investigative Site, Kfar Saba

46202

Novartis Investigative Site, Indianapolis

52621

Novartis Investigative Site, Ramat Gan

53105

Novartis Investigative Site, Bonn

53792

Novartis Investigative Site, Madison

56124

Novartis Investigative Site, Pisa

59000

Novartis Investigative Site, Lille

67000

Novartis Investigative Site, Strasbourg

70809

Novartis Investigative Site, Baton Rouge

75014

Novartis Investigative Site, Paris

79106

Novartis Investigative Site, Freiburg im Breisgau

94275

Novartis Investigative Site, Le Kremlin-Bicêtre

97080

Novartis Investigative Site, Würzburg

115522

Novartis Investigative Site, Moscow

195257

Novartis Investigative Site, Saint Petersburg

400006

Novartis Investigative Site, Cluj-Napoca

420097

Novartis Investigative Site, Kazan'

460000

Novartis Investigative Site, Orenburg

500283

Novartis Investigative Site, Brasov

620028

Novartis Investigative Site, Yekaterinburg

634009

Novartis Investigative Site, Tomsk

760012

Novartis Investigative Site, Santiago de Cali

3339419

Novartis Investigative Site, Haifa

5110683

Novartis Investigative Site, Valdivia

7500571

Novartis Investigative Site, Santiago

7500588

Novartis Investigative Site, Santiago

7500710

Novartis Investigative Site, Santiago

02111

Novartis Investigative Site, Boston

C1055AAF

Novartis Investigative Site, Ciudad Autonoma de Bs As

29055 450

Novartis Investigative Site, Vitória

36010 570

Novartis Investigative Site, Juiz de Fora

01244-030

Novartis Investigative Site, São Paulo

M5T 2S8

Novartis Investigative Site, Toronto

G5L 5T1

Novartis Investigative Site, Rimouski

G8Z 1Y2

Novartis Investigative Site, Trois-Rivières

050001

Novartis Investigative Site, Medellín

080002

Novartis Investigative Site, Barranquilla

01307

Novartis Investigative Site, Dresden

115 27

Novartis Investigative Site, Athens

457 8510

Novartis Investigative Site, Nagoya

857-1165

Novartis Investigative Site, Sasebo

710-8522

Novartis Investigative Site, Kurashiki

104-8560

Novartis Investigative Site, Chuo Ku

160 8582

Novartis Investigative Site, Shinjuku-ku

9713 GZ

Novartis Investigative Site, Groningen

3015 CE

Novartis Investigative Site, Rotterdam

2801 951

Novartis Investigative Site, Almada

1050-034

Novartis Investigative Site, Lisbon

1649-035

Novartis Investigative Site, Lisbon

4990 041

Novartis Investigative Site, Ponte de Lima

06591

Novartis Investigative Site, Seoul

113 65

Novartis Investigative Site, Stockholm

06560

Novartis Investigative Site, Ankara

B15 2TH

Novartis Investigative Site, Birmingham

DN2 5LT

Novartis Investigative Site, Doncaster

M13 9WL

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY